139 related articles for article (PubMed ID: 31913261)
41. Validation of the composite organ and hematologic response model for prognostic prediction in a Chinese light chain amyloidosis cohort.
Shen KN; Miao HL; Zhang L; Feng J; Cao XX; Li J
Leuk Lymphoma; 2021 Aug; 62(8):1892-1896. PubMed ID: 33602009
[TBL] [Abstract][Full Text] [Related]
42. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
Warsame R; Bang SM; Kumar SK; Gertz MA; Lacy MQ; Buadi F; Dingli D; Hayman SR; Kapoor P; Kyle RA; Leung N; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Rajkumar SV; Dispenzieri A
Eur J Haematol; 2014 Jun; 92(6):485-90. PubMed ID: 24502602
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
[TBL] [Abstract][Full Text] [Related]
44. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
45. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
46. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
47. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
48. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
[TBL] [Abstract][Full Text] [Related]
49. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
50. Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center.
Wong SW; Toskic D; Warner M; Varga C; Moreno-Koehler A; Fein D; Fogaren T; Lee L; Oliver CM; Guthrie SD; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):759-766. PubMed ID: 28689003
[TBL] [Abstract][Full Text] [Related]
51. [Oral melphalan plus high-dose dexamethasone as first-line therapy for patients with primary light chain amyloidosis].
Zhang CL; Shen KN; Feng J; Cao XX; Mao YY; Zhang L; Su W; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):641-644. PubMed ID: 30180464
[No Abstract] [Full Text] [Related]
52. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.
Muchtar E; Gertz MA; Kyle RA; Lacy MQ; Dingli D; Leung N; Buadi FK; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves W; Kourelis TV; Warsame R; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Rajkumar SV; Kumar SK; Dispenzieri A
Mayo Clin Proc; 2019 Mar; 94(3):472-483. PubMed ID: 30770096
[TBL] [Abstract][Full Text] [Related]
53. Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature.
Qualls DA; Lewis GD; Sanchorawala V; Staron A
Am J Transplant; 2019 Nov; 19(11):3185-3190. PubMed ID: 31207062
[TBL] [Abstract][Full Text] [Related]
54. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
55. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.
Shaulov A; Ganzel C; Benyamini N; Barshay Y; Goldschmidt N; Lavie D; Libster D; Gural A; Avni B; Gatt ME
Am J Hematol; 2017 Feb; 92(2):131-135. PubMed ID: 27804150
[TBL] [Abstract][Full Text] [Related]
56. Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.
Caccialanza R; Palladini G; Klersy C; Cereda E; Bonardi C; Cameletti B; Quarleri L; Montagna E; Foli A; Milani P; Lavatelli F; Marena C; Merlini G
JPEN J Parenter Enteral Nutr; 2014 Sep; 38(7):891-4. PubMed ID: 24072737
[TBL] [Abstract][Full Text] [Related]
57. Future directions in the clinical management of amyloid light-chain amyloidosis.
Haider S; Ahmad N; Anaissie E; Driscoll JJ
Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
[TBL] [Abstract][Full Text] [Related]
58. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
59. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
60. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
